Public Employees Retirement System of Ohio Trims Stock Holdings in Quanterix Co. (NASDAQ:QTRX)

Public Employees Retirement System of Ohio trimmed its holdings in Quanterix Co. (NASDAQ:QTRX) by 23.4% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,120 shares of the company’s stock after selling 2,180 shares during the period. Public Employees Retirement System of Ohio’s holdings in Quanterix were worth $193,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also bought and sold shares of the business. US Bancorp DE grew its stake in Quanterix by 35.6% in the 2nd quarter. US Bancorp DE now owns 1,709 shares of the company’s stock valued at $39,000 after buying an additional 449 shares in the last quarter. The Manufacturers Life Insurance Company grew its position in shares of Quanterix by 3.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 13,899 shares of the company’s stock valued at $313,000 after purchasing an additional 483 shares in the last quarter. Ameritas Investment Partners Inc. grew its position in shares of Quanterix by 20.2% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,909 shares of the company’s stock valued at $66,000 after purchasing an additional 489 shares in the last quarter. Advisor Group Holdings Inc. grew its position in shares of Quanterix by 184.6% during the 1st quarter. Advisor Group Holdings Inc. now owns 885 shares of the company’s stock valued at $404,000 after purchasing an additional 574 shares in the last quarter. Finally, PNC Financial Services Group Inc. grew its position in shares of Quanterix by 73.9% during the 1st quarter. PNC Financial Services Group Inc. now owns 1,845 shares of the company’s stock valued at $53,000 after purchasing an additional 784 shares in the last quarter. 86.48% of the stock is currently owned by hedge funds and other institutional investors.

Quanterix Stock Performance

NASDAQ QTRX opened at $23.56 on Friday. Quanterix Co. has a 52-week low of $10.30 and a 52-week high of $29.70. The company has a market capitalization of $896.69 million, a P/E ratio of -27.40 and a beta of 1.31. The company has a fifty day moving average of $24.81 and a 200-day moving average of $24.38.

Quanterix (NASDAQ:QTRX) last posted its quarterly earnings data on Thursday, February 29th. The company reported ($0.33) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.05). Quanterix had a negative return on equity of 9.15% and a negative net margin of 26.42%. The company had revenue of $31.55 million for the quarter, compared to the consensus estimate of $27.92 million. As a group, analysts forecast that Quanterix Co. will post -1.04 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, Scotiabank boosted their price target on shares of Quanterix from $30.00 to $32.00 and gave the company a “sector outperform” rating in a research report on Monday, March 4th. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $32.00.

Insider Transactions at Quanterix

In other news, Director Laurie J. Olson sold 1,500 shares of Quanterix stock in a transaction on Wednesday, February 14th. The shares were sold at an average price of $24.35, for a total transaction of $36,525.00. Following the completion of the sale, the director now directly owns 15,238 shares of the company’s stock, valued at approximately $371,045.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 6.80% of the stock is currently owned by insiders.

Quanterix Profile

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.